Company Encyclopedia
View More
name
Ark Israel Inno Techno
IZRL.US
News
View More

UroGen Pharma Grants Inducement RSUs to 14 New Employees

UroGen Pharma Ltd. has granted inducement restricted stock units (RSUs) to 14 new employees, with up to 32,500 ordinary shares issuable upon vesting. The RSUs will vest equally over three years, contingent on continued employment. This announcement was published via GlobeNewswire on December 05, 2025.

Reuters·
US
URGN
0.00%
Reuters·
US
URGN
0.00%

JFrog Director Frederic Simon Reports Sale of Common Shares

JFrog Ltd. Director Frederic Simon has reported the sale of common shares of the company. The information was originally published by JFrog Ltd. via the EDGAR system of the U.S. Securities and Exchange Commission on December 4, 2025. This brief was generated by Public Technologies using AI and is for informational purposes only.

Reuters·
US
FROG
0.00%
Reuters·
US
FROG
0.00%

Israel's stock market surpasses U.S. markets since Oct. 7, 2023. Teva, Elbit Systems, Tower Semiconductor with big gains.

Since October 7, 2023, Israel's stock market has been performing better than the U.S. market. U.S.-listed companies such as Teva, Elbit Systems, and Tower Semiconductor have experienced significant increases in their stock prices. Despite the ongoing controversy surrounding Israel's conflict with Hamas, the country's stock market has shown resilience and growth, particularly in the technology sector. This trend suggests a positive investment climate in Israel, reflected by the success of major tech companies.

Unusual Whales·
US
TEVA
0.00%
US
TSEM
0.00%
US
ESLT
0.00%
Unusual Whales·
US
TEVA
0.00%
US
TSEM
0.00%
US
ESLT
0.00%

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound

Teva Pharmaceutical Industries (NYSE:TEVA) has seen a sharp share price rebound after strong Q3 results, with revenue up 3% and improved debt ratios. The stock returned 36% in one month and 46.9% in three months, reaching $27.83. Analysts suggest Teva is 20% undervalued, with potential growth from biosimilars and innovative drugs. However, its high PE ratio of 44.8x raises caution compared to industry averages. Investors are advised to consider risks and opportunities in Teva's turnaround story.

Simplywall·
US
TEVA
0.00%
Simplywall·
US
TEVA
0.00%

AT&T sues generic drugmakers over alleged price-fixing scheme

AT&T and its employee benefit trust have sued dozens of generic drug manufacturers in U.S. federal court, accusing them of orchestrating a conspiracy to inflate prices on hundreds of medications since at least 2009. The lawsuit alleges antitrust violations and seeks unspecified monetary damages. Companies involved include Teva Pharmaceuticals, Sun Pharma, Sandoz, Glenmark, and Amneal. This adds to ongoing private and state enforcement actions targeting generic drug pricing.

Reuters·
US
T
0.00%
US
TEVA
0.00%
Reuters·
US
T
0.00%
US
TEVA
0.00%
© 2025 Longbridge｜Disclaimer